Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804950

Authors

Alexander S Franzen

Martin J Raftery

Gabriele Pecher

Affiliations

Soon will be listed here.

Abstract

Breast cancer is poorly immunogenic due to immunosuppressive mechanisms produced in part by the tumor microenvironment (TME). The TME is a peritumoral area containing significant quantities of (1) cancer-associated fibroblasts (CAF), (2) tumor-infiltrating lymphocytes (TIL) and (3) tumor-associated macrophages (TAM). This combination protects the tumor from effective immune responses. How these protective cell types are generated and how the changes in the developing tumor relate to these subsets is only partially understood. Immunotherapies targeting solid tumors have proven ineffective largely due to this protective TME barrier. Therefore, a better understanding of the interplay between the tumor, the tumor microenvironment and immune cells would both advance immunotherapeutic research and lead to more effective immunotherapies. This review will summarize the current understanding of the microenvironment of breast cancer giving implications for future immunotherapeutic strategies.

Citing Articles

Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.

Han X, Guo Y, Ye H, Chen Z, Hu Q, Wei X Breast Cancer Res. 2024; 26(1):18.

PMID: 38287356 PMC: 10823720. DOI: 10.1186/s13058-024-01776-y.

Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer.

Kim M, Eun N, Ahn S, Kim J, Youk J, Son E Cancers (Basel). 2024; 16(2).

PMID: 38254866 PMC: 10814692. DOI: 10.3390/cancers16020377.

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC).

Huang J, Wu Q, Geller D, Yan Y J Transl Med. 2023; 21(1):815.

PMID: 37968714 PMC: 10652641. DOI: 10.1186/s12967-023-04716-0.

Effect of multiple peritumoral regions of interest ranges based on computed tomography radiomics for the prediction of early recurrence of hepatocellular carcinoma after resection.

Kang W, Cao X, Luo J Quant Imaging Med Surg. 2023; 13(10):6668-6682.

PMID: 37869280 PMC: 10585524. DOI: 10.21037/qims-23-226.

PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis.

Lobrano R, Paliogiannis P, Zinellu A, Palmieri G, Persico I, Mangoni A Curr Oncol. 2023; 30(5):5135-5144.

PMID: 37232846 PMC: 10217767. DOI: 10.3390/curroncol30050388.

References

Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton J, Curbishley S . Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021; 124(11):1759-1776. PMC: 8144577. DOI: 10.1038/s41416-021-01353-6. View

Lum L, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D, Tomashewski E . Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer. J Immunother Cancer. 2021; 9(6). PMC: 8202097. DOI: 10.1136/jitc-2020-002194. View

Loi S, Drubay D, Adams S, Pruneri G, Francis P, Lacroix-Triki M . Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019; 37(7):559-569. PMC: 7010425. DOI: 10.1200/JCO.18.01010. View

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L . Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019; 12(1):86. PMC: 6714445. DOI: 10.1186/s13045-019-0770-1. View

Yuan Y . Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968167. DOI: 10.1101/cshperspect.a026583. View

Polk A, Svane I, Andersson M, Nielsen D . Checkpoint inhibitors in breast cancer - Current status. Cancer Treat Rev. 2017; 63:122-134. DOI: 10.1016/j.ctrv.2017.12.008. View

Cassier P, Italiano A, Gomez-Roca C, Le Tourneau C, Toulmonde M, DAngelo S . Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer. 2020; 141:162-170. DOI: 10.1016/j.ejca.2020.09.038. View

Cichocki F, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H . iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci Transl Med. 2020; 12(568). PMC: 8861807. DOI: 10.1126/scitranslmed.aaz5618. View

Emens L . Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2017; 24(3):511-520. PMC: 5796849. DOI: 10.1158/1078-0432.CCR-16-3001. View

10.

Binnewies M, Pollack J, Rudolph J, Dash S, Abushawish M, Lee T . Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021; 37(3):109844. DOI: 10.1016/j.celrep.2021.109844. View

11.

Shen M, Wang J, Ren X . New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. Front Immunol. 2018; 9:470. PMC: 5852074. DOI: 10.3389/fimmu.2018.00470. View

12.

Daher M, Rezvani K . Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018; 51:146-153. PMC: 6140331. DOI: 10.1016/j.coi.2018.03.013. View

13.

Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y . Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2019; 111(1):47-58. PMC: 6942430. DOI: 10.1111/cas.14230. View

14.

Villacampa G, Tolosa P, Salvador F, Sanchez-Bayona R, Villanueva L, Dienstmann R . Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2022; 104:102352. DOI: 10.1016/j.ctrv.2022.102352. View

15.

Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A . Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2019; 227:119559. PMC: 7238715. DOI: 10.1016/j.biomaterials.2019.119559. View

16.

Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C . Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015; 7(10):1120-34. PMC: 4593730. DOI: 10.1039/c5ib00040h. View

17.

Sakemura R, Hefazi M, Siegler E, Cox M, Larson D, Hansen M . Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022; 139(26):3708-3721. PMC: 11290597. DOI: 10.1182/blood.2021012811. View

18.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

19.

Cottu P, DHondt V, Dureau S, Lerebours F, Desmoulins I, Heudel P . Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018; 29(12):2334-2340. DOI: 10.1093/annonc/mdy448. View

20.

Buisseret L, Garaud S, De Wind A, Van den Eynden G, Boisson A, Solinas C . Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017; 6(1):e1257452. PMC: 5283629. DOI: 10.1080/2162402X.2016.1257452. View